View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 10, 2020

Aro Biotherapeutics signs licensing agreement worth up to $1.4bn

Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins, has signed a licencing deal that can potentially generate up to $1.4bn for the company.

Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins, has signed a licencing deal that can potentially generate up to $1.4bn for the company.

The Philadelphia-based firm entered a licensing and collaboration agreement with Ionis Pharmaceuticals that will enable the latter to leverage Aro’s Centyrin technology to develop targeted cell and tissue-specific delivery of antisense oligonucleotides (ASOs).

The two companies will work together to deliver ASO-Centyrin drug conjugates, created to treat diseases with ‘high unmet medical need’.

Ionis will have global commercialisation rights of all ASO-Centyrin drug conjugates.

In turn, Aro will be eligible for a payment of up to $1.4bn that will include an upfront cash payment, R&D funding and payments on achieving specific development and commercial milestones. Additionally, Aro will receive royalties on net sales.

Aro Biotherapeutics co-founder and CEO Sue Dillon said: “We are excited to partner with Ionis, the premier company in antisense drug discovery and development.

“The collaboration sets the path for creating a new class of innovative medicines with the potential to selectively target ASOs to tissues where the disease occurs, thereby creating more potent drugs.”

Ionis and Aro also agreed to partner on other discovery programmes.

Ionis Pharmaceuticals chief scientific officer C Frank Bennett said: “Through Ionis’ dedication to innovation and to further advancing our antisense technology, we have produced a broad pipeline of potentially transformational medicines for patients.

“We have now entered this licensing and collaboration agreement with Aro to enable our scientists to expand our technology to an even broader array of disease areas, with a goal of providing new treatment options to patients in need.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology